{"id":"bevacizumab-erlotinib","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypertension"},{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Rash"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bevacizumab works by binding to VEGF-A, preventing it from interacting with its receptor and thus inhibiting the formation of new blood vessels that tumors need to grow. Erlotinib, on the other hand, binds to the ATP-binding pocket of EGFR, preventing the receptor from phosphorylating downstream targets and thereby inhibiting cell proliferation and survival signals.","oneSentence":"Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while erlotinib is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:09.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, metastatic colorectal cancer, glioblastoma, breast cancer, renal cell carcinoma"},{"name":"Other cancers"}]},"trialDetails":[{"nctId":"NCT04981509","phase":"PHASE2","title":"Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-10","conditions":"Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma","enrollment":65},{"nctId":"NCT02759614","phase":"PHASE3","title":"Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations","status":"COMPLETED","sponsor":"Guangdong Association of Clinical Trials","startDate":"2016-04-01","conditions":"NSCLC","enrollment":311},{"nctId":"NCT04449874","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-07-29","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors","enrollment":498},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT00405405","phase":"PHASE1","title":"Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2006-12","conditions":"Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer","enrollment":13},{"nctId":"NCT05525858","phase":"","title":"KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2022-09-28","conditions":"Solid Tumor, Advanced Solid Tumor, Metastatic Cancer","enrollment":1000},{"nctId":"NCT05834348","phase":"","title":"A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-23","conditions":"Non-Small Cell Lung Cancer","enrollment":5279},{"nctId":"NCT01130519","phase":"PHASE2","title":"A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-05-06","conditions":"HLRCC, Sporadic Papillary Renal Cell Cancer","enrollment":83},{"nctId":"NCT00708448","phase":"PHASE1","title":"Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients","status":"COMPLETED","sponsor":"University of Utah","startDate":"2008-03-28","conditions":"Cancer, Non Small Cell Lung Cancer","enrollment":26},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT03647592","phase":"","title":"Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Hunan Province Tumor Hospital","startDate":"2018-06-01","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT05904457","phase":"PHASE2","title":"A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2023-01-02","conditions":"Solid Tumors, Advanced Solid Tumors, Metastatic Cancer","enrollment":32},{"nctId":"NCT02045446","phase":"PHASE2","title":"Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-02","conditions":"Stage IV Non-Small Cell Lung Cancer","enrollment":29},{"nctId":"NCT02633189","phase":"PHASE3","title":"Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2016-04","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":200},{"nctId":"NCT00312728","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03","conditions":"Non-Small Cell Lung Cancer, Brain Neoplasms","enrollment":115},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT01180959","phase":"PHASE2","title":"Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-04-14","conditions":"Liver Cancer","enrollment":45},{"nctId":"NCT01562028","phase":"PHASE2","title":"BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2012-06","conditions":"Lung Cancer","enrollment":109},{"nctId":"NCT00553800","phase":"PHASE2","title":"Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2007-07-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":32},{"nctId":"NCT03126799","phase":"PHASE2","title":"A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2016-11-01","conditions":"EGFR Positive Non-small Cell Lung Cancer","enrollment":128},{"nctId":"NCT00393068","phase":"PHASE2","title":"Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2007-02","conditions":"Esophageal Cancer","enrollment":62},{"nctId":"NCT01454102","phase":"PHASE1","title":"Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12-16","conditions":"Non-small Cell Lung Cancer","enrollment":472},{"nctId":"NCT02574078","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-23","conditions":"Non-Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT01197170","phase":"PHASE1","title":"Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-09-07","conditions":"Solid Tumors, Advanced Cancer","enrollment":277},{"nctId":"NCT00130728","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-06-08","conditions":"Non-Small Cell Lung Cancer","enrollment":636},{"nctId":"NCT04575415","phase":"","title":"Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-10-07","conditions":"NSCLC","enrollment":272},{"nctId":"NCT01532089","phase":"PHASE2","title":"Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2012-03-16","conditions":"EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":88},{"nctId":"NCT00543504","phase":"PHASE1","title":"Bevacizumab in Multiple Phase I Combinations","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-10-10","conditions":"Advanced Cancer","enrollment":343},{"nctId":"NCT00436332","phase":"PHASE2","title":"S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2007-07","conditions":"Lung Cancer","enrollment":84},{"nctId":"NCT00445848","phase":"PHASE2","title":"S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2007-07","conditions":"Lung Cancer","enrollment":89},{"nctId":"NCT04257864","phase":"","title":"Bevacizumab Versus Docetaxel/Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2008-11","conditions":"Non Small Cell Lung Cancer","enrollment":58},{"nctId":"NCT02745691","phase":"","title":"Psychometric Properties of the EORTC QLQ-LC29","status":"COMPLETED","sponsor":"University Hospital Regensburg","startDate":"2016-04-01","conditions":"Lung Cancer","enrollment":523},{"nctId":"NCT01182350","phase":"PHASE2","title":"Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)","status":"TERMINATED","sponsor":"Karen D. Wright MD","startDate":"2011-09","conditions":"Diffuse Intrinsic Pontine Glioma","enrollment":53},{"nctId":"NCT02488330","phase":"PHASE3","title":"An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08-27","conditions":"Solid Tumor","enrollment":12},{"nctId":"NCT01116219","phase":"PHASE2","title":"Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2010-06","conditions":"Lung Cancer","enrollment":149},{"nctId":"NCT00354549","phase":"PHASE2","title":"Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2006-01","conditions":"Lung Cancer","enrollment":104},{"nctId":"NCT00996502","phase":"PHASE1, PHASE2","title":"Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer","status":"TERMINATED","sponsor":"Columbia University","startDate":"2006-07","conditions":"Prostate Cancer","enrollment":4},{"nctId":"NCT00733408","phase":"PHASE2","title":"Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2008-04-23","conditions":"Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer","enrollment":59},{"nctId":"NCT00043823","phase":"PHASE1, PHASE2","title":"Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-08-01","conditions":"Lung Cancer","enrollment":41},{"nctId":"NCT00720356","phase":"PHASE2","title":"Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2009-07-07","conditions":"Brain and Central Nervous System Tumors","enrollment":115},{"nctId":"NCT00055913","phase":"PHASE1, PHASE2","title":"Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-03","conditions":"Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","enrollment":58},{"nctId":"NCT00520013","phase":"PHASE2","title":"Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":60},{"nctId":"NCT02655536","phase":"PHASE2","title":"Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-08-01","conditions":"Carcinoma, Non-Small-Cell Lung, Brain Neoplasms","enrollment":109},{"nctId":"NCT00365144","phase":"PHASE2","title":"Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2006-02","conditions":"Pancreatic Cancer","enrollment":36},{"nctId":"NCT00619424","phase":"PHASE1","title":"A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-15","conditions":"Lung Cancer, Non-Small Cell","enrollment":58},{"nctId":"NCT01344824","phase":"PHASE2","title":"Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2010-03","conditions":"Lung Cancer","enrollment":38},{"nctId":"NCT01351415","phase":"PHASE3","title":"A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-06-25","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":485},{"nctId":"NCT00881751","phase":"PHASE2","title":"Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2009-03","conditions":"Liver Cancer","enrollment":95},{"nctId":"NCT00054132","phase":"PHASE2","title":"Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-12","conditions":"Recurrent Breast Carcinoma, Stage IV Breast Cancer","enrollment":38},{"nctId":"NCT00280150","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2006-01","conditions":"Lung Cancer","enrollment":46},{"nctId":"NCT00550537","phase":"PHASE2","title":"Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2007-10","conditions":"Lung Cancer","enrollment":116},{"nctId":"NCT00366457","phase":"PHASE2","title":"Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-08","conditions":"Pancreatic Cancer, Adenocarcinoma of the Pancreas","enrollment":32},{"nctId":"NCT00307736","phase":"PHASE1, PHASE2","title":"Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2006-05","conditions":"Rectal Cancer, Adenocarcinoma of the Rectum","enrollment":32},{"nctId":"NCT00392665","phase":"PHASE2","title":"Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2006-10","conditions":"Squamous Cell Carcinoma of the Head and Neck (SCCHN)","enrollment":36},{"nctId":"NCT00351039","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2006-07","conditions":"Non-Small Cell Lung Cancer","enrollment":8},{"nctId":"NCT01383148","phase":"PHASE2, PHASE3","title":"Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Transgene","startDate":"2012-04","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":222},{"nctId":"NCT00811993","phase":"PHASE1","title":"A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Neoplasms","enrollment":104},{"nctId":"NCT00260364","phase":"PHASE1, PHASE2","title":"Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2005-11","conditions":"Pancreatic Cancer","enrollment":44},{"nctId":"NCT00737243","phase":"PHASE2","title":"Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2008-08","conditions":"Carcinoma","enrollment":289},{"nctId":"NCT00614653","phase":"PHASE1","title":"Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-01","conditions":"Pancreatic Cancer","enrollment":17},{"nctId":"NCT00705874","phase":"PHASE1","title":"Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma","status":"COMPLETED","sponsor":"Progen Pharmaceuticals","startDate":"2006-05","conditions":"Cancer","enrollment":172},{"nctId":"NCT01047059","phase":"PHASE2","title":"Molecular Imaging With Erlotinib and Bevacizumab","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2010-01","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":40},{"nctId":"NCT00257608","phase":"PHASE3","title":"A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-01","conditions":"Non-Small Cell Lung Cancer","enrollment":1145},{"nctId":"NCT00203424","phase":"PHASE2","title":"Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib","status":"COMPLETED","sponsor":"Translational Oncology Research International","startDate":"2006-01","conditions":"Prostate Cancer","enrollment":23},{"nctId":"NCT02701231","phase":"NA","title":"Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2015-11","conditions":"Lung Neoplasms","enrollment":200},{"nctId":"NCT00367601","phase":"PHASE2","title":"Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Nasser Hanna, M.D.","startDate":"2006-08","conditions":"Lung Cancer","enrollment":25},{"nctId":"NCT00265824","phase":"PHASE3","title":"Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2005-05","conditions":"Colorectal Cancer","enrollment":700},{"nctId":"NCT00749567","phase":"PHASE2","title":"Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Hellenic Oncology Research Group","startDate":"2008-07","conditions":"Non-small-cell Lung Cancer","enrollment":13},{"nctId":"NCT00585377","phase":"PHASE2","title":"Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Utah","startDate":"2007-08","conditions":"Cancer","enrollment":50},{"nctId":"NCT00925769","phase":"PHASE1","title":"ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-01","conditions":"Pancreatic Cancer","enrollment":32},{"nctId":"NCT00442507","phase":"PHASE2","title":"Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2007-03","conditions":"Esophageal Neoplasms, Esophageal Diseases","enrollment":6},{"nctId":"NCT00365391","phase":"PHASE2","title":"Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-08","conditions":"Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer","enrollment":27},{"nctId":"NCT00735306","phase":"PHASE1","title":"Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Duke University","startDate":"2008-07","conditions":"Pancreatic Cancer","enrollment":12},{"nctId":"NCT00621049","phase":"PHASE2","title":"Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2007-12","conditions":"Non-Small Cell Lung Cancer","enrollment":112},{"nctId":"NCT01229813","phase":"PHASE3","title":"Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Lund University Hospital","startDate":"2010-10","conditions":"Colorectal Cancer","enrollment":233},{"nctId":"NCT00543842","phase":"PHASE1","title":"Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-12","conditions":"Rectal Cancer","enrollment":19},{"nctId":"NCT01135498","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-11","conditions":"Colorectal Cancer","enrollment":90},{"nctId":"NCT00276575","phase":"PHASE1","title":"Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Herbert Hurwitz, MD","startDate":"2005-03","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":65},{"nctId":"NCT00800202","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04","conditions":"Non-Small Cell Lung Cancer","enrollment":91},{"nctId":"NCT00525525","phase":"PHASE2","title":"Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-09","conditions":"Glioblastoma, Gliosarcoma","enrollment":74},{"nctId":"NCT00531960","phase":"PHASE2","title":"A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Non-Small Cell Lung Cancer","enrollment":124},{"nctId":"NCT01214720","phase":"PHASE3","title":"A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Pancreatic Cancer","enrollment":607},{"nctId":"NCT00605722","phase":"PHASE2","title":"A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-03","conditions":"Liver Cancer","enrollment":51},{"nctId":"NCT00101348","phase":"PHASE1, PHASE2","title":"Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-01","conditions":"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip","enrollment":66},{"nctId":"NCT00369889","phase":"PHASE2","title":"A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2006-08","conditions":"Thymic Cancer, Thymoma","enrollment":18},{"nctId":"NCT00976677","phase":"PHASE2","title":"Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-01","conditions":"Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":10},{"nctId":"NCT00356889","phase":"PHASE2","title":"Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-05","conditions":"Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Gastrointestinal Cancer","enrollment":56},{"nctId":"NCT00081614","phase":"PHASE2","title":"A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2004-03","conditions":"Renal Cell Carcinoma, Metastases","enrollment":100},{"nctId":"NCT00091026","phase":"PHASE2","title":"Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-07","conditions":"Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer","enrollment":143},{"nctId":"NCT00126542","phase":"PHASE2","title":"Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-04","conditions":"Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer","enrollment":35},{"nctId":"NCT00193154","phase":"PHASE2","title":"OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2003-02","conditions":"Kidney Cancer","enrollment":63},{"nctId":"NCT00360360","phase":"PHASE2","title":"Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2006-07","conditions":"Neoplasm, Unknown Primary","enrollment":60},{"nctId":"NCT00633529","phase":"PHASE1","title":"Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2007-11","conditions":"Non-Small Cell Lung Cancer","enrollment":36},{"nctId":"NCT00060411","phase":"PHASE1","title":"A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-06","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":24},{"nctId":"NCT00466687","phase":"PHASE2","title":"Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2004-09","conditions":"Melanoma","enrollment":34},{"nctId":"NCT00702975","phase":"PHASE2","title":"Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2008-09","conditions":"Locally Advanced Non-Small Cell Lung Cancer, NSCLC","enrollment":35},{"nctId":"NCT00536640","phase":"PHASE2","title":"Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab","status":"COMPLETED","sponsor":"Aktion Bronchialkarzinom e.V.","startDate":"2007-11","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":224},{"nctId":"NCT00047307","phase":"PHASE1","title":"Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-08","conditions":"Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer","enrollment":46},{"nctId":"NCT00671970","phase":"PHASE2","title":"Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-02","conditions":"Glioblastoma, Gliosarcoma","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":62,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["bevacizumab (Avastin)","erlotinib (Tarceva)","Avastin, Tarceva"],"phase":"phase_3","status":"active","brandName":"bevacizumab, erlotinib","genericName":"bevacizumab, erlotinib","companyName":"Swiss Cancer Institute","companyId":"swiss-cancer-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), while erlotinib is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). Used for Non-small cell lung cancer, metastatic colorectal cancer, glioblastoma, breast cancer, renal cell carcinoma, Other cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}